Using convalescent plasma, Griffith University researchers have identified how it may be possible to make a future vaccine that will provide protection against all major strains of COVID-19
A Griffith University-led research team has discovered how a therapeutic target common among debilitating neurodegenerative disorders is activated, which could help accelerate drug development.
Students, family and friends attended the first in-person ceremonies to be held in more than a year.
Griffith University Institute for Glycomics researchers are closer to the development of a new vaccine aimed at preventing the deadly Streptococcus A (Strep A), which kills more than 500,000 people globally per year.
Philanthropist and business leader Warren von Bibra has been bestowed the title Doctor of the University (DUniv).
Griffith University’s Institute for Glycomics has been awarded $2.66 million in Ideas Grant funding from the National Health and Medical Research Council (NHMRC) to aid four vital research projects. Director Professor Mark von Itzstein AO was delighted with the grant awards and said they cemented the Institute’s reputation as a leading biomedical research institute. “Our […]
A new experimental drug to treat sepsis has now entered the next stage of clinical trials in patients in Australia after successfully completing Phase 1a trials in healthy volunteers, reports Griffith University’s Institute for Glycomics. The sepsis drug candidate, co-invented by researchers led by Professor Mark von Itzstein AO at the Institute for Glycomics and […]